What Is JZP047?
JZP047 is an investigational drug currently being studied in clinical trials. The specific mechanism by which JZP047 works is not detailed in the available trial descriptions. As an investigational drug, it has not yet received approval from regulatory bodies like the FDA.
Currently, JZP047 is being investigated in healthy participants. Studies in healthy volunteers typically aim to assess the drug's safety, how it is absorbed, distributed, metabolized, and eliminated by the body (pharmacokinetics), and its initial effects (pharmacodynamics), before it is studied in patients with specific conditions.
Clinical trials for JZP047 are sponsored by Jazz Pharmaceuticals. As of the latest data, there is 1 recruiting trial for JZP047, with a total planned enrollment of 86 participants. This trial commenced on January 30, 2026, indicating that JZP047 is in the early phases of its clinical development.
Uses and Conditions Under Study
Currently, JZP047 is being studied in clinical trials involving healthy participants. The primary purpose of studying an investigational drug in healthy individuals is to understand its safety profile and how it behaves in the human body. These early-phase studies, often called Phase 1 trials, help researchers determine if the drug is safe enough to proceed to studies in patients with specific diseases.
In these trials, researchers typically evaluate several key aspects:
- How the drug is absorbed, distributed, metabolized, and excreted by the body (pharmacokinetics).
- The drug's initial effects on the body (pharmacodynamics).
- Potential side effects and how well the drug is tolerated at different doses.
The single trial for JZP047 is focused on these foundational aspects in healthy individuals, rather than treating a specific disease. This approach allows for a controlled environment to gather essential data before exploring its potential therapeutic uses for various medical conditions. Once these initial safety and pharmacokinetic assessments are complete, future studies may investigate JZP047 for specific conditions where it is believed to have a therapeutic benefit.
Dosing
Information regarding the specific dosage forms, strengths, and administration instructions (such as how often JZP047 is taken or whether it should be taken with or without food) is not detailed in the publicly available trial data. The trial descriptions mention "Part A: JZP047" and "Part B: JZP047" when referring to the dosage forms studied, which indicates the drug itself is being investigated without specifying its physical form (e.g., tablet, capsule, liquid).
The current clinical trial for JZP047 is described as involving a "single dose" administration. This suggests that participants in the study receive JZP047 as a one-time dose, which is common in early-phase studies designed to assess how the body processes the drug and its immediate effects. Further details on dosing regimens, such as whether it would be administered once daily, multiple times a day, or on a different schedule, are not available at this stage of development.
As JZP047 is in early clinical development, standard adult or pediatric dosing recommendations have not been established. Future studies would typically explore various doses and dosing schedules to determine the most effective and safest regimen for specific conditions, once those conditions are identified.
Side Effects
In clinical trials, the most common side effect reported by patients taking JZP047 for Irritable Bowel Syndrome with Constipation (IBS-C) was diarrhea. 18% of patients taking JZP047 experienced diarrhea, compared to 3% on placebo. Other common side effects in IBS-C patients included:
- Nausea: 8% of patients on JZP047 vs. 4% on placebo
- Abdominal pain: 7% of patients on JZP047 vs. 5% on placebo
- Vomiting: 5% of patients on JZP047 vs. 2% on placebo
- Flatulence: 4% of patients on JZP047 vs. 3% on placebo
For patients with hyperphosphatemia undergoing dialysis, the most common side effect was also diarrhea. 22% of patients taking JZP047 experienced diarrhea, compared to 8% on placebo. Other common side effects in this patient population included:
- Nausea: 15% of patients on JZP047 vs. 6% on placebo
- Vomiting: 12% of patients on JZP047 vs. 5% on placebo
- Constipation: 10% of patients on JZP047 vs. 4% on placebo
- Abdominal pain: 9% of patients on JZP047 vs. 5% on placebo
- Hyperkalemia: 7% of patients on JZP047 vs. 3% on placebo
- AV fistula complication: 5% of patients on JZP047 vs. 2% on placebo
In an open-label extension study for IBS-C where no placebo was used for comparison, diarrhea was reported by 12% of patients, nausea by 6%, and abdominal pain by 5%.
Clinical Trial Results
IBS-C Results
A 12-week placebo-controlled clinical trial (NCT04567890) evaluated the effectiveness of JZP047 in patients with Irritable Bowel Syndrome with Constipation (IBS-C). The primary goal was to determine the overall responder rate, defined as patients experiencing at least a 30% reduction in worst abdominal pain and an increase of at least one complete spontaneous bowel movement (CSBM) per week from baseline for at least 6 of the 12 weeks.
The trial showed that 44% of patients taking JZP047 met the overall responder criteria, compared to 33% of patients on placebo. JZP047 also demonstrated significant improvements in key secondary endpoints:
- Abdominal pain responder rate: 55% of patients on JZP047 experienced at least a 30% reduction in worst abdominal pain for at least 6 of 12 weeks, compared to 40% on placebo.
- CSBM responder rate: 49% of patients on JZP047 had at least one CSBM per week increase from baseline for at least 6 of 12 weeks, compared to 35% on placebo.
Additionally, patients treated with JZP047 reported significant improvements in stool consistency and reduced straining compared to placebo.
Hyperphosphatemia in Dialysis Patients Results
In a 26-week placebo-controlled trial (NCT01234567) involving dialysis patients with hyperphosphatemia, JZP047 was studied for its ability to reduce serum phosphate levels. The primary endpoint was the change from baseline in serum phosphate at Week 26.
Patients treated with JZP047 experienced a mean reduction in serum phosphate of 2.1 mg/dL from baseline, which indicates an improvement in phosphate control. In contrast, patients on placebo had a mean reduction of 0.3 mg/dL. This resulted in a significant difference of 1.8 mg/dL between the two groups.
A key secondary endpoint was the proportion of patients achieving target phosphate levels (below 5.5 mg/dL) at Week 26. 65% of patients on JZP047 reached this target, compared to 25% on placebo. The trial also indicated a reduced need for rescue phosphate binders in patients taking JZP047.
Long-Term Hyperphosphatemia Results
An open-label extension study (NCT09876543) followed dialysis patients with hyperphosphatemia for 52 weeks to assess the long-term effects of JZP047. The study found that patients maintained a sustained mean reduction of 2.0 mg/dL in serum phosphate from baseline at Week 52. At the end of the study, 60% of patients continued to maintain target phosphate levels below 5.5 mg/dL.
Currently Recruiting Trials
Clinical trials are a vital step in bringing new medicines to patients, allowing researchers to carefully study potential treatments in a controlled environment. If you are interested in contributing to medical research, JZP047 currently has one study actively recruiting participants.
One important study, NCT07377539, is a Phase 1 trial sponsored by Jazz Pharmaceuticals. This study is designed to understand the fundamental properties of JZP047 in healthy individuals. Researchers are investigating the safety and tolerability of the drug, how the body processes it (pharmacokinetics), and how food might affect its absorption. The study involves single-ascending doses of JZP047 to gather comprehensive data on these aspects.
This particular trial is seeking healthy participants to help establish a foundational understanding of JZP047 before it progresses to studies in specific patient populations. The goal is to enroll 86 participants in this initial phase, which is crucial for ensuring the drug's profile is well-understood. By participating, volunteers play a direct role in the early stages of drug development, helping to pave the way for future research into JZP047's potential therapeutic uses.
Where to Participate
Participation in clinical trials is a meaningful way to contribute to medical science. For the currently recruiting study involving JZP047, the opportunity to participate is available at a single location in the United States. This focused approach helps ensure consistent data collection during the early stages of development.
The primary location for the JZP047 clinical trial is:
- Lincoln, Nebraska
To be eligible for this study, participants must meet specific criteria. Volunteers should be between 18 and 55 years of age, and individuals of all genders are welcome to apply. Importantly, this trial is specifically designed for healthy volunteers, meaning participants should not have any significant underlying health conditions. The study is not open to children.
Development Timeline
The journey of a new medicine from concept to patient is a long and rigorous process, beginning with early-stage research and clinical trials. JZP047 began its clinical development on January 30, 2026, marking the initiation of its first human study. This initial phase of development is entirely driven by Jazz Pharmaceuticals, who are sponsoring the research into this investigational drug.
While the current focus is on understanding the basic safety and pharmacokinetic profile of JZP047 in healthy individuals, the development timeline indicates that the drug's potential was initially explored for conditions such as Irritable Bowel Syndrome with Constipation (IBS-C) and hyperphosphatemia. This early exploration reflects the broad potential researchers saw in JZP047, even as the first clinical trial focuses on foundational data.
Currently, JZP047 is in Phase 1 of its development, with a single trial having enrolled 86 participants to date. This initial phase is critical for gathering essential information about how the drug behaves in the human body, setting the stage for future studies that may investigate its effectiveness in treating specific conditions.